Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

64.41
-0.2800-0.43%
Pre-market: 64.600.1900+0.29%06:26 EDT
Volume:6.57M
Turnover:423.82M
Market Cap:131.12B
PE:14.18
High:65.05
Open:64.57
Low:64.26
Close:64.69
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.93
T/O Rate:0.32%
Dividend:2.51
Dividend Rate:3.90%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.87
PE(LYR):18.62

Loading ...

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Reuters
·
Sep 03

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Dow Jones
·
Sep 03

Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 03

London Midcaps Lead Losses as Rising Gilt Yields Weigh; Reckitt Gains

Reuters
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Oxford BioMedica Slides as Novartis, Bristol-Myers Squibb Pause CAR-T Autoimmune Trials

Reuters
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Bristol-Myers Squibb Spokesperson - Implemented a Voluntary Pause to Review Clinical Data Across Our Zola-Cel Program

THOMSON REUTERS
·
Sep 01

Rpt: Bristol-Myers Squibb Also Pauses Similar Trials as a Precautionary Measure- WSJ

THOMSON REUTERS
·
Sep 01

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Dow Jones
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study

TIPRANKS
·
Aug 31

Procter & Gamble, Target, Canopy, Bristol, Oklo Insider Shock

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Sweden's Elicera Therapeutics Q2 Loss Widens

Reuters
·
Aug 28

Bristol-Myers Squibb Extends Deucravacitinib Program, Signaling Long-Term Autoimmune Ambitions

TIPRANKS
·
Aug 28

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

Top Bristol-Myers Squibb Executive Makes Notable Move With Recent Stock Sale

TIPRANKS
·
Aug 27

Bristol Myers Squibb SVP, Controller Phil M. Holzer Sells 500 Shares for $33,750

Reuters
·
Aug 27

Bloomsbury Ties Executive Share Awards to Long-Term Performance Targets

TIPRANKS
·
Aug 26